$DXCM
DEXCOM INC Stock $dxcm

$dxcm Overview Financials Valuation SEC Filings Company Website

2013 Q2 Form 10-Q Financial Statement

#000109355713000083 Filed on August 07, 2013

Income Statement

Concept	2013 Q2	2012 Q2	2012 Q1
Revenue	$35.80M	$23.50M	$20.10M
YoY Change	52.34%	9.81%	41.55%
Cost Of Revenue	$13.90M	$12.20M	$10.70M
YoY Change	13.93%	27.8%	17.58%
Gross Profit	$21.90M	$11.20M	$9.400M
YoY Change	95.54%	-5.88%	84.31%
Gross Profit Margin	61.17%	47.66%	46.77%
Selling, General & Admin	$20.70M	$15.90M	$15.40M
YoY Change	30.19%	29.86%	43.93%
% of Gross Profit	94.52%	141.96%	163.83%
Research & Development	$11.10M	$10.00M	$9.400M
YoY Change	11.0%	42.53%	49.21%
% of Gross Profit	50.68%	89.29%	100.0%
Depreciation & Amortization	$1.600M	$1.500M	$1.200M
YoY Change	6.67%	66.67%	50.0%
% of Gross Profit	7.31%	13.39%	12.77%
Operating Expenses	$31.80M	$25.90M	$24.80M
YoY Change	22.78%	34.2%	45.88%
Operating Profit	-$9.900M	-$14.70M	-$15.40M
YoY Change	-32.65%	98.94%	29.41%
Interest Expense	$200.0K	$0.00	$0.00
YoY Change		-100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$10.10M	-$14.70M	-$15.40M
YoY Change	-31.29%	99.54%	29.41%
Income Tax	$0.00	$0.00	-$1.300M
% Of Pretax Income
Net Earnings	-$10.10M	-$14.70M	-$14.10M
YoY Change	-31.29%	98.65%	19.49%
Net Earnings / Revenue	-28.21%	-62.55%	-70.15%
Basic Earnings Per Share
Diluted Earnings Per Share	-$142.5K	-$214.3K	-$208.0K
COMMON SHARES
Basic Shares Outstanding	70.90M shares
Diluted Shares Outstanding	70.90M shares

Balance Sheet

Concept	2013 Q2	2012 Q2	2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$46.40M	$61.20M	$70.20M
YoY Change	-24.19%	-41.71%	88.2%
Cash & Equivalents	$28.20M	$6.000M	$5.100M
Short-Term Investments	$18.20M	$55.20M	$65.10M
Other Short-Term Assets	$2.800M	$2.500M	$2.100M
YoY Change	12.0%	-37.5%	-40.0%
Inventory	$7.300M	$7.378M	$8.000M
Prepaid Expenses
Receivables	$17.70M	$12.90M	$12.50M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$74.20M	$83.99M	$92.80M
YoY Change	-11.66%	-32.26%	70.59%
LONG-TERM ASSETS
Property, Plant & Equipment	$19.10M	$17.77M	$16.20M
YoY Change	7.5%	48.07%	38.46%
Goodwill	$3.200M	$3.162M
YoY Change	1.2%
Intangibles	$3.900M	$4.462M
YoY Change	-12.6%
Long-Term Investments
YoY Change
Other Assets	$900.0K	$98.00K	$1.200M
YoY Change	818.37%	-75.5%	200.0%
Total Long-Term Assets	$28.10M	$26.53M	$25.20M
YoY Change	5.92%	113.94%	106.56%
TOTAL ASSETS
Total Short-Term Assets	$74.20M	$83.99M	$92.80M
Total Long-Term Assets	$28.10M	$26.53M	$25.20M
Total Assets	$102.3M	$110.5M	$118.0M
YoY Change	-7.44%	-18.97%	77.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.800M	$2.000M	$2.000M
YoY Change	40.0%	-4.76%	0.0%
Accrued Expenses	$16.40M	$13.40M	$12.30M
YoY Change	22.39%	44.09%	78.26%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.200M
YoY Change
Total Short-Term Liabilities	$21.10M	$16.96M	$16.10M
YoY Change	24.4%	22.91%	38.79%
LONG-TERM LIABILITIES
Long-Term Debt	$5.800M	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.100M	$1.551M	$2.300M
YoY Change	99.87%	55.1%	43.75%
Total Long-Term Liabilities	$3.100M	$1.551M	$2.300M
YoY Change	99.87%	55.1%	43.75%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.10M	$16.96M	$16.10M
Total Long-Term Liabilities	$3.100M	$1.551M	$2.300M
Total Liabilities	$30.00M	$19.21M	$18.40M
YoY Change	56.14%	29.82%	39.39%
SHAREHOLDERS EQUITY
Retained Earnings	-$466.8M	-$419.9M
YoY Change	11.17%
Common Stock	$539.1M	$511.2M
YoY Change	5.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$72.30M	$91.30M	$99.60M
YoY Change
Total Liabilities & Shareholders Equity	$102.3M	$110.5M	$118.0M
YoY Change	-7.44%	-18.97%	77.18%

Cashflow Statement

Concept	2013 Q2	2012 Q2	2012 Q1
OPERATING ACTIVITIES
Net Income	-$10.10M	-$14.70M	-$14.10M
YoY Change	-31.29%	98.65%	19.49%
Depreciation, Depletion And Amortization	$1.600M	$1.500M	$1.200M
YoY Change	6.67%	66.67%	50.0%
Cash From Operating Activities	$900.0K	-$6.300M	-$10.20M
YoY Change	-114.29%	152.0%	9.68%
INVESTING ACTIVITIES
Capital Expenditures	-$2.000M	-$2.900M	$2.300M
YoY Change	-31.03%	141.67%	-227.78%
Acquisitions
YoY Change
Other Investing Activities	$8.100M	$9.600M	$14.00M
YoY Change	-15.62%	-125.26%	62.79%
Cash From Investing Activities	$6.100M	$6.800M	$11.70M
YoY Change	-10.29%	-117.39%	72.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$1.100M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.300M	500.0K	$1.100M
YoY Change	360.0%	-99.3%	-26.67%
NET CHANGE
Cash From Operating Activities	900.0K	-6.300M	-$10.20M
Cash From Investing Activities	6.100M	6.800M	$11.70M
Cash From Financing Activities	2.300M	500.0K	$1.100M
Net Change In Cash	9.300M	1.000M	$2.600M
YoY Change	830.0%	-96.68%	-360.0%
FREE CASH FLOW
Cash From Operating Activities	$900.0K	-$6.300M	-$10.20M
Capital Expenditures	-$2.000M	-$2.900M	$2.300M
Free Cash Flow	$2.900M	-$3.400M	-$12.50M
YoY Change	-185.29%	161.54%	66.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1100000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-200000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-800000	USD
	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	-100000	USD
	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	100000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	600000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	800000	USD
	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	0	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	8900000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5200000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3400000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.42
CY2012Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	8700000	USD
CY2013Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	539100000	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	522600000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9000000	USD
CY2013Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	9100000	USD
CY2012Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3900000	USD
CY2013Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2800000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-200000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-500000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-100000	USD
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-100000	USD
CY2012	us-gaap	Acquisition Costs AcquisitionCosts	300000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11400000	USD
CY2013Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6400000	USD
CY2012Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4800000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	200000	USD
CY2012Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10700000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10600000	shares
CY2013Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10600000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10700000	shares
CY2013Q2	us-gaap	Assets Assets	102300000	USD
CY2012Q4	us-gaap	Assets Assets	106000000	USD
CY2013Q2	us-gaap	Assets Current AssetsCurrent	74200000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	77600000	USD
CY2013Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	18200000	USD
CY2012Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	40600000	USD
CY2012Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	40600000	USD
CY2013Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	18200000	USD
	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	0	USD
CY2012	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	0	USD
	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	0	USD
CY2012	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	0	USD
CY2012Q4	us-gaap	Business Acquisition Equity Interest Issued Or Issuable Value Assigned BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned	3900000	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2100000	USD
CY2013Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3100000	USD
CY2012Q1	us-gaap	Business Acquisition Equity Interest Issued Or Issuable Value Assigned BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned	3900000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28200000	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6000000	USD
CY2012Q4	us-gaap	Business Acquisition Percentage Of Voting Interests Acquired BusinessAcquisitionPercentageOfVotingInterestsAcquired	1
CY2012Q1	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	6100000	USD
CY2012Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	2200000	USD
CY2012Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	2200000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8100000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2600000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	20100000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3400000	USD
CY2013Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	46400000	USD
CY2013Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	22000000	USD
CY2012Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	4500000	USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71500000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69700000	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69500000	shares
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	71200000	shares
CY2013Q2	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	100000	USD
CY2012Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	100000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21200000	USD
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10100000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28800000	USD
CY2012Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14700000	USD
CY2012Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	10900000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	26100000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	20500000	USD
CY2013Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	13700000	USD
CY2012Q2	us-gaap	Cost Of Revenue CostOfRevenue	12200000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	22900000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	27000000	USD
CY2013Q2	us-gaap	Cost Of Revenue CostOfRevenue	13900000	USD
CY2012Q4	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2016-11-01
CY2012Q4	us-gaap	Debt Instrument Unused Borrowing Capacity Amount DebtInstrumentUnusedBorrowingCapacityAmount	13000000	USD
CY2012	us-gaap	Debt Issuance Costs DebtIssuanceCosts	1100000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
CY2012Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2200000	USD
CY2012Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1700000	USD
CY2012Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1700000	USD
CY2013Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	700000	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1400000	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	600000	USD
CY2013Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	151300000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2700000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3400000	USD
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9200000	USD
CY2013Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10100000	USD
CY2013Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	50400000	USD
CY2013Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	1300000	USD
CY2013Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	700000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	700000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1000000	USD
CY2012Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	700000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	2200000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	0	USD
CY2013Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	0	USD
CY2012Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	0	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	0	USD
CY2012Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	1200000	USD
CY2013Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3900000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	1200000	USD
CY2013Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	0	USD
CY2013Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2000000	USD
CY2011Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	USD
CY2013Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2700000	USD
CY2013Q2	us-gaap	Goodwill Goodwill	3200000	USD
CY2012Q4	us-gaap	Goodwill Goodwill	3200000	USD
CY2013Q2	us-gaap	Gross Profit GrossProfit	21900000	USD
	us-gaap	Gross Profit GrossProfit	20600000	USD
	us-gaap	Gross Profit GrossProfit	38400000	USD
CY2012Q2	us-gaap	Gross Profit GrossProfit	11200000	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10100000	USD
CY2012Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14700000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21200000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-30000000	USD
CY2012Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1200000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2013Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2012Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1300000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	800000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-500000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1800000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	400000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1300000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	300000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	800000	USD
CY2012Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4200000	USD
CY2013Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	0	USD
CY2012Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	0	USD
	us-gaap	Interest And Other Income InterestAndOtherIncome	0	USD
	us-gaap	Interest And Other Income InterestAndOtherIncome	100000	USD
	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	400000	USD
CY2013Q2	us-gaap	Interest Expense InterestExpense	200000	USD
CY2012Q2	us-gaap	Interest Expense InterestExpense	0	USD
CY2013Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3500000	USD
CY2012Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4500000	USD
CY2013Q2	us-gaap	Inventory Net InventoryNet	7300000	USD
CY2012Q4	us-gaap	Inventory Net InventoryNet	7400000	USD
CY2013Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3100000	USD
CY2012Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2500000	USD
CY2013Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	700000	USD
CY2012Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	400000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	29000000	USD
CY2013Q2	us-gaap	Liabilities Liabilities	30000000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	106000000	USD
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	102300000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19500000	USD
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	21100000	USD
CY2012Q4	us-gaap	Line Of Credit LineOfCredit	15000000	USD
CY2013Q2	us-gaap	Long Term Debt LongTermDebt	7000000	USD
CY2013Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	200000	USD
CY2013Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	2300000	USD
CY2013Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	2300000	USD
CY2013Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2200000	USD
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	42300000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Organization and Business</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring (“CGM”) systems for ambulatory use by people with diabetes and by healthcare providers in the hospital for the treatment of people with and without diabetes. Unless the context requires otherwise, the terms “we,” “us,” “our,” the “company,” or “DexCom” refer to DexCom, Inc. and its subsidiaries.</font></div></div>
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1600000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5000000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18300000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18700000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3600000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16500000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-21200000	USD
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-14700000	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-10100000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-28800000	USD
	us-gaap	Operating Expenses OperatingExpenses	50700000	USD
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	25900000	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	31800000	USD
	us-gaap	Operating Expenses OperatingExpenses	59200000	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-14700000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-20800000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-30100000	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9900000	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	9300000	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1300000	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	2600000	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	2700000	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	2700000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1500000	USD
CY2012Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	500000	USD
CY2013Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	700000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1100000	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2800000	USD
CY2013Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4100000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1100000	USD
CY2013Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	900000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2012Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2013Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2013Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2012Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	6100000	USD
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000.0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q2	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2012Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2013Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2800000	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2000000	USD
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain reclassifications have been made to the prior period consolidated financial statements and notes to conform to the current year presentation.</font></div></div>
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5000000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1600000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	31000000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	65800000	USD
	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1400000	USD
CY2013Q2	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	-800000	USD
CY2012Q2	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	-500000	USD
	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	900000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18900000	USD
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19100000	USD
CY2013Q2	us-gaap	Recorded Unconditional Purchase Obligation Due Within One Year RecordedUnconditionalPurchaseObligationDueWithinOneYear	11600000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20400000	USD
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10000000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19500000	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11100000	USD
CY2013Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1000000	USD
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1000000	USD
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1000000	USD
CY2013Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1000000	USD
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-466800000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-445600000	USD
	us-gaap	Revenues Revenues	65400000	USD
CY2013Q2	us-gaap	Revenues Revenues	35800000	USD
	us-gaap	Revenues Revenues	43500000	USD
CY2012Q2	us-gaap	Revenues Revenues	23400000	USD
CY2012Q4	dxcm	Debt Instrument Basis Spread On Treasury Variable Rate DebtInstrumentBasisSpreadOnTreasuryVariableRate	0.0694
CY2013Q2	dxcm	Development And Other Cost Of Sales DevelopmentAndOtherCostOfSales	200000	USD
CY2012Q2	dxcm	Development And Other Cost Of Sales DevelopmentAndOtherCostOfSales	1300000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	40100000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	63300000	USD
CY2012Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	21500000	USD
CY2013Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	35500000	USD
	dxcm	Development And Other Cost Of Sales DevelopmentAndOtherCostOfSales	900000	USD
	dxcm	Development And Other Cost Of Sales DevelopmentAndOtherCostOfSales	2400000	USD
	dxcm	Development Grant And Other Revenue DevelopmentGrantAndOtherRevenue	3400000	USD
CY2012Q2	dxcm	Development Grant And Other Revenue DevelopmentGrantAndOtherRevenue	1900000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	9000000	USD
CY2013Q2	us-gaap	Secured Debt Current SecuredDebtCurrent	1200000	USD
CY2012Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	200000	USD
CY2013Q2	us-gaap	Secured Long Term Debt SecuredLongTermDebt	5800000	USD
CY2012Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	6800000	USD
CY2012Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15900000	USD
CY2013Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	20700000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	38800000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	31200000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	11400000	USD
CY2012Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	300000	USD
CY2013Q2	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	300000	USD
CY2012Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	300000	USD
CY2012Q2	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	400000	USD
CY2013Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	200000	USD
CY2011Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	300000	USD
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	77000000	USD
CY2013Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	72300000	USD
CY2012	us-gaap	Tax Credit Carryforward Expiration Date TaxCreditCarryforwardExpirationDate	2020-01-01
CY2013Q2	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	800000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates. Significant estimates include excess or obsolete inventories, valuation of inventory, warranty accruals, employee bonus, clinical study expenses, allowances for returned product, allowance for bad debt, deferral period for recognizing revenue on future performance obligations, accounting for the SweetSpot acquisition including contingent consideration, and share-based compensation expense. Excess and obsolete inventories are estimated by identifying the amount of on hand and on order materials compared to expected future sales, taking into account clinical trial and development usage along with new product introductions. Employee bonus estimates are based, in part, on the 2013 bonus plan’s authorized target bonus amounts to be awarded from the bonus pool based on the weighted average achievement of certain objectives. Clinical trial expenses are accrued based on estimates of progress under related contracts and include initial set up costs as well as ongoing monitoring over multiple sites in the U.S. and abroad. An allowance for refunds for returned products is determined by analyzing the timing and amounts of past refund activity and considering the impact of newly introduced products.</font></div></div>
	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	0	USD
	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1300000	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	68200000	shares
CY2012Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	68600000	shares
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	70900000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	70300000	shares
CY2013Q2	dxcm	Accounts Receivable Net Of Allowance And Sales Returns Current AccountsReceivableNetOfAllowanceAndSalesReturnsCurrent	17700000	USD
CY2012Q4	dxcm	Accounts Receivable Net Of Allowance And Sales Returns Current AccountsReceivableNetOfAllowanceAndSalesReturnsCurrent	19500000	USD
CY2013Q2	dxcm	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	1000000	USD
CY2012Q4	dxcm	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	700000	USD
CY2013Q2	dxcm	Acquisition Related Contingent Consideration Short Term AcquisitionRelatedContingentConsiderationShortTerm	1000000	USD
CY2012Q4	dxcm	Acquisition Related Contingent Consideration Short Term AcquisitionRelatedContingentConsiderationShortTerm	1200000	USD
CY2012	dxcm	Business Acquisition Contingent Consideration Settlement BusinessAcquisitionContingentConsiderationSettlement	1100000	USD
CY2012	dxcm	Business Acquisition Contingent Consideration Settlement Shares Issued BusinessAcquisitionContingentConsiderationSettlementSharesIssued	89296	shares
CY2013Q2	dxcm	Business Acquisition Equity Interests Issued Or Issuable Additional Number Of Shares Issuable BusinessAcquisitionEquityInterestsIssuedOrIssuableAdditionalNumberOfSharesIssuable	267880	shares
CY2012Q1	dxcm	Business Combination Contingent Consideration Liability Shares BusinessCombinationContingentConsiderationLiabilityShares	357176	shares
CY2012Q4	dxcm	Clinical Trials ClinicalTrials	100000	USD
CY2013Q2	dxcm	Clinical Trials ClinicalTrials	200000	USD
CY2013Q2	dxcm	Contingent Consideration Fair Value Disclosure ContingentConsiderationFairValueDisclosure	2700000	USD
CY2012Q4	dxcm	Contingent Consideration Fair Value Disclosure ContingentConsiderationFairValueDisclosure	1700000	USD
CY2013Q2	dxcm	Development Grant And Other Revenue DevelopmentGrantAndOtherRevenue	300000	USD
	dxcm	Development Grant And Other Revenue DevelopmentGrantAndOtherRevenue	2100000	USD
	dxcm	Fair Value Of Contingent Consideration FairValueOfContingentConsideration	1000000	USD
	dxcm	Fair Value Of Contingent Consideration FairValueOfContingentConsideration	700000	USD
	dxcm	Increase Decrease In Restricted Cash Investing And Financing Activities IncreaseDecreaseInRestrictedCashInvestingAndFinancingActivities	-100000	USD
	dxcm	Increase Decrease In Restricted Cash Investing And Financing Activities IncreaseDecreaseInRestrictedCashInvestingAndFinancingActivities	0	USD
CY2012Q4	dxcm	Line Of Credit Facility Borrowing Base Percentage Of Eligible Accounts LineOfCreditFacilityBorrowingBasePercentageOfEligibleAccounts	0.80
	dxcm	Maximum Percentage Of Ownership Change To Retain Tax Credit Carryforwards MaximumPercentageOfOwnershipChangeToRetainTaxCreditCarryforwards	0.50
	dxcm	Option To Renew Lease OptionToRenewLease	P5Y
	dxcm	Potential Rental Rate Adjustment Maximum PotentialRentalRateAdjustmentMaximum	0.040
	dxcm	Potential Rental Rate Adjustment Minimum PotentialRentalRateAdjustmentMinimum	0.025
CY2012Q4	dxcm	Prime Rate Plus PrimeRatePlus	0.005
CY2013Q2	dxcm	Recorded Unconditional Purchase Obligation Due Within One Year Maximum Term RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm	P1Y
	dxcm	Sales Return Coverage Period SalesReturnCoveragePeriod	P30D
CY2012Q2	dxcm	Standard Product Warranty Accrual Charges To Costs And Expenses StandardProductWarrantyAccrualChargesToCostsAndExpenses	600000	USD
CY2013Q2	dxcm	Standard Product Warranty Accrual Charges To Costs And Expenses StandardProductWarrantyAccrualChargesToCostsAndExpenses	900000	USD
	dxcm	Standard Product Warranty Accrual Charges To Costs And Expenses StandardProductWarrantyAccrualChargesToCostsAndExpenses	1400000	USD
	dxcm	Standard Product Warranty Accrual Charges To Costs And Expenses StandardProductWarrantyAccrualChargesToCostsAndExpenses	1000000	USD
CY2012Q4	dxcm	Term Loan Advances Aggregate Amount TermLoanAdvancesAggregateAmount	7000000	USD
CY2012Q4	dxcm	Term Loan Debt TermLoanDebt	20000000	USD
	dxcm	Term Of Lease TermOfLease	P3Y
CY2013Q2	dxcm	Working Capital WorkingCapital	53100000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Period End Date DocumentPeriodEndDate	2013-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001093557
CY2013Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	71376433	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	DEXCOM INC
	dei	Trading Symbol TradingSymbol	DXCM

Files In Submission

Name	View Source	Status
0001093557-13-000083-index-headers.html	Edgar Link	pending
0001093557-13-000083-index.html	Edgar Link	pending
0001093557-13-000083.txt	Edgar Link	pending
0001093557-13-000083-xbrl.zip	Edgar Link	pending
dxcm-06302013x10q.htm	Edgar Link	pending
dxcm-20130630.xml	Edgar Link	completed
dxcm-20130630.xsd	Edgar Link	pending
dxcm-20130630_cal.xml	Edgar Link	unprocessable
dxcm-20130630_def.xml	Edgar Link	unprocessable
dxcm-20130630_lab.xml	Edgar Link	unprocessable
dxcm-20130630_pre.xml	Edgar Link	unprocessable
dxcm06302013ex3101.htm	Edgar Link	pending
dxcm06302013ex3102.htm	Edgar Link	pending
dxcm06302013ex3201.htm	Edgar Link	pending
dxcm06302013ex3202.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R31.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R32.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R33.xml	Edgar Link	unprocessable
R34.htm	Edgar Link	pending
R34.xml	Edgar Link	unprocessable
R35.htm	Edgar Link	pending
R35.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DXCM
DEXCOM INC Stock $dxcm

2013 Q2 Form 10-Q Financial Statement

#000109355713000083 Filed on August 07, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DXCM DEXCOM INC Stock $dxcm

2013 Q2 Form 10-Q Financial Statement

#000109355713000083 Filed on August 07, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DXCM
DEXCOM INC Stock $dxcm